Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Leap Therapeutics, Inc. (LPTX : NSDQ)

• Company Description    Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. Number of Employees: 36

• Price / Volume Information    Yesterday's Closing Price: $1.31 Daily Weekly Monthly 20 Day Moving Average: 891,230 shares Shares Outstanding: 88.32 (millions) Market Capitalization: $115.70 (millions) Beta: 0.71 52 Week High: $4.17 52 Week Low: $0.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.39% 0.38% 12 Week -37.32% -31.99% Year To Date -59.57% -51.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47 THORNDIKE STREET SUITE B1-1 - CAMBRIDGE,MA 02141 USA ph: 617-714-0360 fax: - ir@leaptx.com http://www.leaptx.com

• General Corporate Information    Officers Douglas E. Onsi - Chief Executive Officer; President; Chief Financia Christopher K. Mirabelli - Chairman Monica M. Bertagnolli - Director James Cavanaugh - Director Thomas Dietz - Director Peer Information Leap Therapeutics, Inc. (CORR.) Leap Therapeutics, Inc. (RSPI) Leap Therapeutics, Inc. (CGXP) Leap Therapeutics, Inc. (BGEN) Leap Therapeutics, Inc. (GTBP) Leap Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 52187K101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 88.32 Most Recent Split Date: (:1) Beta: 0.71 Market Capitalization: $115.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.17 Price/Cash Flow: - Price / Sales: 77.13 EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: 10.00% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% ROE 03/31/22 - -47.38 12/31/21 - -55.42 09/30/21 - -63.02 ROA 03/31/22 - -42.92 12/31/21 - -49.24 09/30/21 - -54.86 Current Ratio 03/31/22 - 14.29 12/31/21 - 11.70 09/30/21 - 11.11 Quick Ratio 03/31/22 - - 12/31/21 - 11.70 09/30/21 - 11.11 Operating Margin 03/31/22 - - 12/31/21 - -2,705.80 09/30/21 - -2,433.93 Net Margin 03/31/22 - - 12/31/21 - -2,705.80 09/30/21 - -2,433.93 Pre-Tax Margin 03/31/22 - -3,720.27 12/31/21 - -2,707.40 09/30/21 - -2,434.07 Book Value 03/31/22 - 1.12 12/31/21 - 1.22 09/30/21 - 1.33 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©